takeaway
disappoint core growth miss vs biopharma
plan lead reduc outlook impli third
yr slow growth continu diverg tool peer said
visibl low fundament pictur remain quit mix
prospect market cap acceler buyback offer
nt support like put floor stock maintain hold pt
multipl factor drive miss revenu growth miss expect
mark second time year come short intern target
gov t/academ remain healthi biopharma industri
soft deceler q/q mainli attribut shortfal india rupe
pharma weak estimate neg off-set solid growth china
 somewhat better us pharma demand soft
later read-through hesit read much miss first life
core growth strong across board second think slow biopharma
trend mostli wat-specif like due share loss lack innov
guidanc cut cut core growth outlook guid
well vs prior assum materi yr-end budget flush dynam
q/q rebound end-market given weaker top line trim ep guid
mid-pt despit acceler buy-back activ plan
vs model lower net interest expens
tap balanc sheet buy-back call indic
plan reach net debt/ebitda end net cash
suggest could deploy toward acceler share repurchas next yr
current market cap main driver upwardli revis ep forecast
factor buyback net debt
stock see support
ep discount peer histor absolut average view
warrant given deceler core growth vs inconsist
execut late would also impli premium
average premium outsid buy-back support somewhat easi comp move
visibl re-acceler core growth low
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
million except per share
page
pleas see import disclosur inform page report
vs growthv expectationsprior yearforecastreportedactualpercentactualpercentepsnet product expens share share analysisgross research sg oper incom incom net
million except per share
page
pleas see import disclosur inform page report
histor earn per flow cash cash flow cash flow per cash net interest free cash stock-bas sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per
histor project quarterli incom statement
million except per share
page
pleas see import disclosur inform page report
histor net product expens share share analysisgross sg oper incom incom net growth analysisnet
water lead supplier analyt instrument consum servic pharmaceut life scienc biochem industri
academ govern organ conduct research qa/qc activ
pt repres discount horizon dcf impli ev ebitda ufcf risk margin expans
pt repres horizon dcf impli nopat compound-annual-growth-rate ev ufcf prem vs peer
brandon couillard certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
matthew stanton certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
michael koban certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within period
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate secur averag
secur price consist expect total return price appreci plu yield plu minu within period
under-perform rate secur averag secur price consist expect total return price appreci plu yield minu
less within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/
jefferi polici
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic secur regul
prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project opinion
invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil expect total
return next month price target base sever methodolog may includ restrict analys market
premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
page
pleas see import disclosur inform page report
